Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

F Izzo
F Izzo
National Cancer Institute

Ann Surg 2000 Sep;232(3):381-91

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC).

Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue heating.

Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease.

Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69%) and 34 patients (31%), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6%); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45. 5%), but 56 patients (50.9%) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7%) after RFA.

Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.

Download full-text PDF

September 2000
12 Reads

Publication Analysis

Top Keywords

patients cirrhosis
developed patients
110 patients
local tumor
treated rfa
radiofrequency ablation
cirrhosis hcc
rfa patients
rfa median
69% patients
months percutaneous
performed 69%
percutaneous intraoperative
patients 31%
intraoperative rfa

Similar Publications

Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.

Ann Surg Oncol 2005 Aug 20;12(8):616-28. Epub 2005 Jun 20.

Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, 77030-4009, USA.

Background: Radiofrequency ablation (RFA) offers an alternative treatment in some unresectable hepatocellular carcinoma (HCC) patients with disease confined to the liver. We prospectively evaluated survival rates in patients with early-stage, unresectable HCC treated with RFA.

Methods: All patients with HCC treated with RFA between September 1, 1997, and July 31, 2002, were prospectively evaluated. Read More

View Article
August 2005

[Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy].

Zhonghua Wai Ke Za Zhi 2005 Aug;43(15):980-4

Ultrasound Department of Clinical Oncology School, Peking University, Beijing 100036, China.

Objective: To assess the efficiency and safety of radiofrequency ablation (RFA) of recurrent hepatocellular carcinoma (RHCC) after hepatectomy and to investigate efficacy of RFA for patients with early and late phase recurrence, separately, setting 1 year as the cut-off between the early and late phases.

Methods: A total of 42 patients with 77 RHCC and a history of hepatic resection for hepatocellular carcinoma (HCC) underwent ultrasound-guided percutaneous radiofrequency ablation in our department and entered this study (RHCC group). The average diameter of RHCC was (3. Read More

View Article
August 2005

Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a 'cooled-tip needle'. A preliminary clinical experience.

G Francica G Marone

Eur J Ultrasound 1999 May;9(2):145-53

Divisione di Gastroenterologia, Ospedale 'Cardinale Ascalesi', ASL Napoli 1, Via Egiziaca a Forcella 44, Napoli, Italy.

Objective: Radiofrequency hyperthermia using the newly-developed 'cooled-tip' needle has recently been proposed as a therapeutic modality for hepatocellular carcinoma (HCC). Herein we report our preliminary results on feasibility and effectiveness of the thermal ablation of mono- or pauci-focal hepatocellular carcinoma with the cooled-tip needle.

Materials And Methods: We treated 15 cirrhotic patients (mean age 68. Read More

View Article
May 1999

Laparoscopic ultrasound with radiofrequency ablation in cirrhotic patients with hepatocellular carcinoma: technique and technical considerations.

Am Surg 2001 Dec;67(12):1181-4

Department of Surgery, University of California, Irvine Medical Center, Orange 92868, USA.

The optimal treatment for hepatocellular carcinoma (HCC) is surgical resection. However, only a small percentage of patients are operative candidates. CT-guided percutaneous radiofrequency ablation (RFA) has been shown to be efficacious in treatment of unresectable HCC. Read More

View Article
December 2001